(Q47738386)

5 February 2018

title

FOLFIRI with cetuximab or bevacizumab: FIRE-3-authors' reply (English)

1 reference

5 February 2018

1 reference

1 reference

Volker Heinemann

1

1 reference

5 February 2018

Sebastian Stintzing

series ordinal

2

1 reference

5 February 2018

publication date

24 November 2014

1 reference

5 February 2018

Lancet Oncology Commission

published in

1 reference

5 February 2018

volume

15

1 reference

5 February 2018

issue

13

1 reference

5 February 2018

page(s)

e583-4

1 reference

5 February 2018

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971036-8

7 January 2021

Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971036-8

7 January 2021

Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971036-8

7 January 2021

Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971036-8

7 January 2021

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971036-8

7 January 2021

10.1016/S1470-2045(14)71036-8

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018